Testing 611 for Teen Eczema (moderate to severe)
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 to 17 years old and weigh at least 66 pounds.
- You have moderate to severe eczema that covers at least 10% of your body and hasn't responded well to topical treatments like creams or ointments.
- You haven't used certain strong eczema treatments (like JAK inhibitors or dupilumab) within the past few weeks to months.
- You do not have active infections, cancer (in the last 5 years), or a history of certain serious health conditions.
- You are willing to use a moisturizer twice a day and avoid pregnancy or sperm donation during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine (called 611) given as an injection to children with moderate-to-severe eczema that hasn't improved with creams. The goal is to see if it can reduce itching and clear the rash.
This study tests a new medicine, MG-K10, given as an injection, to see if it can reduce eczema symptoms like itching and skin rash in teenagers. It's for teens whose eczema is not well controlled with topical treatments.
This trial tests an investigational drug called SM17 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if SM17 can reduce itching and skin symptoms when topical treatments haven't worked well enough.
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
This trial tests a new injectable medicine called FB825 for people with moderate to severe eczema that hasn't improved enough with standard creams. The study aims to see if FB825 can reduce itching and skin symptoms safely.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
Hear when a new Dermatitis, Atopic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.